Literature DB >> 6593114

Changing metastatic patterns of osteosarcoma.

A E Giuliano, S Feig, F R Eilber.   

Abstract

The clinical courses of 111 patients with osteosarcoma treated at UCLA between 1971 and 1982 were reviewed to ascertain the evolution of the natural history of this disease. Only patients with classic high-grade intraosseous osteosarcoma of the extremity, scapula, or pelvis were considered. Patients with low-grade parosteal osteosarcomas; primary osteosarcomas of the face, skull, vertebra, or ribs; and osteosarcomas arising in Paget's disease or previously irradiated bones were not included. Fifty-nine patients developed clinically evident distant metastases. Of these, 36 developed pulmonary metastases alone as the initial site of recurrence. Eighteen of 19 (94.7%) patients treated between 1971 and 1974 by amputation alone developed pulmonary relapse as the initial site of recurrence, whereas only 18 of 40 patients (45%) treated after 1974 with surgery and adjuvant chemotherapy developed pulmonary metastases alone as the initial site of recurrence. Although no patients in the early group developed an extrapulmonary metastasis as the initial site of recurrence, 11 of 40 patients (27.5%) treated with adjuvant chemotherapy developed an extrapulmonary metastasis as the initial site of recurrent disease, and 11 patients developed simultaneous pulmonary and extrapulmonary metastases. Although it is impossible to attribute this alteration in metastatic pattern to adjuvant chemotherapy alone, it is apparent that nonpulmonary metastases are becoming more common among patients currently treated for osteosarcoma.

Entities:  

Mesh:

Year:  1984        PMID: 6593114     DOI: 10.1002/1097-0142(19841115)54:10<2160::aid-cncr2820541016>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Unusual abdominal metastases in osteosarcoma.

Authors:  Simon Berhe; Enrico Danzer; Paul Meyers; Gerald Behr; Michael P LaQuaglia; Anita P Price
Journal:  J Pediatr Surg Case Rep       Date:  2018-01

Review 2.  Brain metastasis in pediatric extracranial solid tumors: survey and literature review.

Authors:  Rejin Kebudi; Inci Ayan; Omer Görgün; Fulya Yaman Ağaoğlu; Sema Vural; Emin Darendeliler
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 3.  The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Zhen Wang
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

4.  [New morphologic findings in malignant bone tumors].

Authors:  G Delling
Journal:  Langenbecks Arch Chir       Date:  1987

5.  Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck.

Authors:  Stanley I Gutiontov; Zachary S Zumsteg; Benjamin H Lok; Sean Berry; Chiaojung J Tsai; Sean M McBride; Nadeem Riaz; Oren Cahlon; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2017-03-14

6.  Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival.

Authors:  Darshana D Rasalkar; Winnie C W Chu; Vincent Lee; Bhawan K Paunipagar; Frankie W T Cheng; Chi Kong Li
Journal:  Pediatr Radiol       Date:  2010-09-03

7.  Orbital metastasis: a rare presentation of osteosarcoma.

Authors:  Suresh V S Attili; Ankit Jain; Kamal V Saini; Ullas Batra; K Govind Babu; K V Sajeevan; Siddarth Biswas
Journal:  Int Ophthalmol       Date:  2007-10-23       Impact factor: 2.031

8.  Changing metastatic patterns of a transplantable rat osteosarcoma.

Authors:  F Wingen; E Weber
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

9.  Morphology of pulmonary metastases from osteosarcoma during chemotherapy.

Authors:  T Derstappen; A Roessner; K M Müller; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

10.  Results of thoracotomy in osteogenic sarcoma with pulmonary metastases.

Authors:  S R Carter; R J Grimer; R S Sneath; H R Matthews
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.